[HTML][HTML] The changing epidemiology of human monkeypox—A potential threat? A systematic review
…, L Chen, F Lienert, H Weidenthaler… - PLoS neglected …, 2022 - journals.plos.org
Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like
disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the …
disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the …
[HTML][HTML] Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox
…, D Schmidt, J Hornung, H Weidenthaler… - … England Journal of …, 2019 - Mass Medical Soc
Background Many countries have stockpiled vaccines because of concerns about the
reemergence of smallpox. Traditional smallpox vaccines are based on replicating vaccinia viruses; …
reemergence of smallpox. Traditional smallpox vaccines are based on replicating vaccinia viruses; …
One-and two-dose vaccinations with modified vaccinia Ankara-Bavarian nordic induce durable B-cell memory responses comparable to replicating smallpox vaccines
…, G Silbernagl, R Nichols, H Weidenthaler… - The Journal of …, 2023 - academic.oup.com
Background Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is
approved for smallpox and monkeypox prevention, immunological persistence and booster …
approved for smallpox and monkeypox prevention, immunological persistence and booster …
Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine
…, S Vidojkovic, LM Chen, H Weidenthaler… - The Journal of …, 2021 - academic.oup.com
Background Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease
in young children and the elderly. Protective immunity is not generated after repeated …
in young children and the elderly. Protective immunity is not generated after repeated …
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
…, SJ Lawrence, JT Stapleton, H Weidenthaler… - Vaccine, 2020 - Elsevier
Traditional replicating smallpox vaccines are associated with serious safety concerns in the
general population and are contraindicated in immunocompromised individuals. However, …
general population and are contraindicated in immunocompromised individuals. However, …
[HTML][HTML] The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine …
A Volkmann, AL Williamson, H Weidenthaler… - Vaccine, 2021 - Elsevier
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed
to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The …
to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The …
[HTML][HTML] Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled …
…, C Kreusel, S De Carli, TP Meyer, H Weidenthaler… - PloS one, 2018 - journals.plos.org
Background Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced
development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-…
development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-…
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
…, TPH Meyer, E Jordan, T Adams, H Weidenthaler… - Vaccine, 2020 - Elsevier
Respiratory disease caused by RSV infection is recognized as a severe public health issue
in infants, young children and elderly with no specific treatment option. Vaccination may be …
in infants, young children and elderly with no specific treatment option. Vaccination may be …
Reduced respiratory syncytial virus load, symptoms, and infections: a human challenge trial of MVA-BN-RSV vaccine
…, D Schmidt, VA Jenkins, H Weidenthaler… - The Journal of …, 2023 - academic.oup.com
Background Respiratory syncytial virus (RSV) causes significant disease burden in older
adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV …
adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV …
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
…, E Menius, K Nopora, J Maclennan, H Weidenthaler - Vaccine, 2023 - Elsevier
Since vaccination remains the only effective protection against orthopox virus-induced
diseases such as smallpox or monkeypox, the strategic use and stockpiling of these vaccines …
diseases such as smallpox or monkeypox, the strategic use and stockpiling of these vaccines …